drugset / Trial / NCT06923527
Circulating Tumor DNA
Phase 2
Recruiting
50 enrolled
Yale University
Johns Hopkins University · collabStemline Therapeutics, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in three separate phases: screening, treatment, and follow-up.
Timeline
- Start
- 2025-09-30
- Primary completion
- 2027-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elacestrant | Other / unclassified | 345 mg | Oral |